TrialCompass™ TCL
Back to trials
Phase 1RecruitingPriority 4 · Lower priorityNCT07195916

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

ClinicalTrials.gov

Plain-language summary

This trial is testing INCA036873 (an investigational intravenous drug) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

INCA036873 (DRUG): Intravenously (IV)

  • INCA036873

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

NCT07195916

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing INCA036873 (an investigational intravenous drug) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

INCA036873 (DRUG): Intravenously (IV)

Drugs / treatments: INCA036873

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 280 patients

Primary endpoint: Part 1A : Occurrence of Dose Limiting Toxicities (DLTs); Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Ages: 18 Years to —

Start date: 2026-01-08 | Est. completion: 2028-08-18

Locations

8 US sites · 22 total

California, Michigan, Nebraska, New York, Tennessee, Texas

Contact

Incyte Corporation Call Center (US) | medinfo@incyte.com | 1.855.463.3463

Sponsor: Incyte Corporation (INDUSTRY)

Tags

All T-cell lymphomas · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07195916

Prepared using TrialCompass (trialcompass.com) on August 18, 2026. For informational purposes only. Always discuss with your healthcare team.